Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

In the Q4 earnings call, the company stated that it has focused its R&D portfolio on four key therapeutic areas: oncology, ...

4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Andexxa (andexanet alfa) is approved for the reversal of anticoagulation by Factor Xa inhibitors – Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Pfizer/Bristol-Myers Squibb's Eliquis ...

But the same quarter last year included a revenue reversal tied to the planned return ... Pfizer said its blood thinner Eliquis, which is co-marketed by Bristol Myers Squibb, also helped drive ...

See "Use of Non-GAAP Financial Information". U.S. revenues increased 9% to $8.6 billion, primarily driven by higher demand for the Growth Portfolio and Eliquis, partially offset by the impact of ...

We made great progress with commercial execution and achieved growth across our product portfolio for full-year 2024, including $3.4 billion in revenue from our legacy Seagen portfolio, as well as ...

also has shown better than 90% inhibition of factor XI, with about 66% less bleeding compared with apixaban in patients with AF ... One catch is that, so far, there are no reversal agents for factor ...